Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus FULVICIN U F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus FULVICIN U F.
FOCINVEZ vs FULVICIN-U/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Category C
Category C
Antifungal
Antifungal